SCHEMBL6423669

SCHEMBL6423669

COCCOc1ncccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
KDM1A O60341 1/20 0.38
POLB P06746 3/20 0.35
MPO P05164 1/20 0.35
RAB9A P51151 2/20 0.34
TLR7 Q9NYK1 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
PKM P14618 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33
ACACB O00763 1/20 0.33
NUDT1 P36639 1/20 0.33
GRM4 Q14833 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280446 0.77 NPC1 (0.46) RAB9AL3MBTL1SMN1; SMN2HSD17B10NPC1
SCHEMBL23405912 0.76 CYP1A2 (0.46) TSHRPOLBRAB9AL3MBTL1PKM
SCHEMBL25680732 0.76 TSHR (0.39) TSHRTLR7ACACBNUDT1
SCHEMBL18881729 0.76 NCF1 (0.40) L3MBTL1GRM4HTTMAPK1NPSR1
SCHEMBL25659408 0.76 TSHR (0.41) TSHRPOLBMPOTLR7L3MBTL1
SCHEMBL4268840 0.75 CYP2D6 (0.48) RAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL15423536 0.75 TSHR (0.37) TSHRPOLBRAB9AL3MBTL1GRM4
SCHEMBL20334287 0.75 KDM4E (0.37) TSHRRAB9ATLR7ACACBNUDT1
SCHEMBL16416281 0.75 EDNRA (0.38) TSHRKDM1AACACB
SCHEMBL16002427 0.74 TSHR (0.42) TSHRPOLBRAB9ATLR7HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572128-A2 RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) Sirna Therapeutics, Inc. (US) 2005-09-14 EP claimed
JP-2005517427-A 2005-06-16 JP claimed
EP-1430157-A4 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SIRNA THERAPEUTICS INC (US) 2005-06-08 EP claimed
US-20040209831-A1 RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) SIRNA THERAPEUTICS, INC. 2004-10-21 US claimed
EP-1430157-A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) Sirna Therapeutics, Inc. (US) 2004-06-23 EP claimed
WO-2003070750-A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS SIRNA THERAPEUTICS, INC (US) 2003-08-28 WO claimed
WO-2003070193-A2 RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SIRNA THERAPEUTICS, INC (US) 2003-08-28 WO claimed
US-20250034121-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2025-01-30 US disclosed
CN-119173512-A Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof 英矽智能科技知识产权有限公司 2024-12-20 CN disclosed
WO-2024125451-A1 PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-20 WO disclosed
WO-2024125464-A1 TETRAHYDROISOQUINOLIN-ONE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-20 WO disclosed
WO-2023083297-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-05-19 WO disclosed
EP-3825312-A1 INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS Gilead Pharmasset LLC (US) 2021-05-26 EP disclosed
US-20080027037-A1 Cyclic compounds TANABE SEIYAKU CO., LTD. 2008-01-31 US disclosed
US-20080027037-A1 Cyclic compounds TANABE SEIYAKU CO., LTD. 2008-01-31 US disclosed
US-7273868-B2 Pyrazine derivatives TANABE SEIYAKU CO., LTD. (JP) 2007-09-25 US disclosed
US-7273868-B2 Pyrazine derivatives TANABE SEIYAKU CO., LTD. (JP) 2007-09-25 US disclosed
US-7220736-B2 Pyrimidine compounds TANABE SEIYAKU CO., LTD. (JP) 2007-05-22 US disclosed
US-7220736-B2 Pyrimidine compounds TANABE SEIYAKU CO., LTD. (JP) 2007-05-22 US disclosed
EP-1277741-A1 CYCLIC COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2003-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209831-A1 RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) SNRPF, ZC3HAV1, SRRT TSHR 3572/4885KDM1A 3470/4885POLB 2632/4885
US-20250034121-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS GPR183, GPR180, GPR65 TSHR 2452/4885KDM1A 4047/4885POLB 4084/4885
US-20080027037-A1 Cyclic compounds PDE4A, PDE4B, PDE3B TSHR 809/4885KDM1A 2487/4885POLB 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.